Literature DB >> 30923072

Epidemiology and implications of concurrent diagnosis of eosinophilic oesophagitis and IBD based on a prospective population-based analysis.

Berkeley N Limketkai1, Shailja C Shah2, Ikuo Hirano3, Emanuelle Bellaguarda3, Jean-Frederic Colombel4.   

Abstract

OBJECTIVE: Eosinophilic oesophagitis (EoO) and IBD are immune-mediated diseases of the gastrointestinal tract with possible overlapping pathogenic mechanisms. Our aim was to define the epidemiology and clinical implications of concurrent EoO and IBD diagnoses.
DESIGN: We conducted a prospective cohort analysis using the Truven MarketScan database (2009-2016) to estimate the incidence and prevalence of EoO in patients with Crohn's disease (CD) or UC and vice versa. Cox proportional hazards and Kaplan-Meier methods were used to estimate the risk of EoO-related or IBD-related complications among patients with concurrent diagnoses.
RESULTS: Among 134 013 536 individuals, the incidence of EoO, CD and UC were 23.1, 51.2 and 55.2 per 100 000 person-years, respectively. The risk of EoO was higher among patients with CD (incidence rate ratio [IRR] 5.4, p<0.01; prevalence ratio (PR) 7.8, p<0.01) or UC (IRR 3.5, p<0.01; PR 5.0, p<0.01), while the risk of IBD was higher among patients with EoO (CD: IRR 5.7, p<0.01; PR 7.6, p<0.01; UC: IRR 3.4, p<0.01; PR 4.9, p<0.01) versus individuals without either diagnosis. Concurrent diagnosis of EoO and IBD was associated with greater composite risk of IBD-related complications (CD: adjusted HR (aHR) 1.09, p=0.01; UC: aHR 1.10, p=0.04) but lower composite risk of EoO-related complications (aHR 0.59; p<0.01).
CONCLUSION: Based on a population-based prospective cohort analysis, the risk of EoO is significantly higher among patients with IBD and vice versa. Concurrent diagnoses might modify the risk of IBD-related and EoO-related complications. Studies defining the mechanisms underlying these observations are needed. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  epidemiology; inflammatory bowel disease; oesophagitis

Mesh:

Year:  2019        PMID: 30923072     DOI: 10.1136/gutjnl-2018-318074

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  11 in total

1.  Mucosal Eosinophilia Is an Independent Predictor of Vedolizumab Efficacy in Inflammatory Bowel Diseases.

Authors:  Erin M Kim; Cara Randall; Renee Betancourt; Staci Keene; Amy Lilly; Mark Fowler; Evan S Dellon; Hans H Herfarth
Journal:  Inflamm Bowel Dis       Date:  2020-07-17       Impact factor: 5.325

2.  British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults.

Authors:  Anjan Dhar; Hasan N Haboubi; Stephen E Attwood; Marcus K H Auth; Jason M Dunn; Rami Sweis; Danielle Morris; Jenny Epstein; Marco R Novelli; Hannah Hunter; Amanda Cordell; Sharon Hall; Jamal O Hayat; Kapil Kapur; Andrew Robert Moore; Carol Read; Sarmed S Sami; Paul J Turner; Nigel J Trudgill
Journal:  Gut       Date:  2022-05-23       Impact factor: 31.793

Review 3.  How to approach adult patients with asymptomatic esophageal eosinophilia.

Authors:  Philipp Schreiner; Luc Biedermann; Thomas Greuter; Benjamin L Wright; Alex Straumann
Journal:  Dis Esophagus       Date:  2021-01-11       Impact factor: 3.429

4.  A genome-wide association meta-analysis identifies new eosinophilic esophagitis loci.

Authors:  Xiao Chang; Michael March; Frank Mentch; Kenny Nguyen; Joseph Glessner; Huiqi Qu; Yichuan Liu; Glen Furuta; Seema Aceves; Nirmala Gonsalves; Kari Nadeau; Antonella Cianferoni; Jonathan Spergel; Patrick Sleiman; Hakon Hakonarson
Journal:  J Allergy Clin Immunol       Date:  2021-09-25       Impact factor: 14.290

5.  Comorbid Diagnosis of Eosinophilic Esophagitis and Inflammatory Bowel Disease in the Pediatric Population.

Authors:  Hillary Moore; Joshua Wechsler; Carrie Frost; Elizabeth Whiteside; Robert Baldassano; Jonathan Markowitz; Amanda B Muir
Journal:  J Pediatr Gastroenterol Nutr       Date:  2021-03-01       Impact factor: 3.288

Review 6.  Approaches and Challenges to Management of Pediatric and Adult Patients With Eosinophilic Esophagitis.

Authors:  Ikuo Hirano; Glenn T Furuta
Journal:  Gastroenterology       Date:  2019-12-10       Impact factor: 22.682

7.  Phenotype and Natural History of Inflammatory Bowel Disease in Patients With Concomitant Eosinophilic Esophagitis.

Authors:  Michael J Mintz; Ashwin N Ananthakrishnan
Journal:  Inflamm Bowel Dis       Date:  2021-03-15       Impact factor: 5.325

Review 8.  Eosinophilic esophagitis-established facts and new horizons.

Authors:  Luc Biedermann; Alex Straumann; Thomas Greuter; Philipp Schreiner
Journal:  Semin Immunopathol       Date:  2021-06-07       Impact factor: 9.623

Review 9.  Early Life Risk Factors in Pediatric EoE: Could We Prevent This Modern Disease?

Authors:  Martina Votto; Gian Luigi Marseglia; Maria De Filippo; Ilaria Brambilla; Silvia Maria Elena Caimmi; Amelia Licari
Journal:  Front Pediatr       Date:  2020-05-29       Impact factor: 3.418

Review 10.  Upper Gastrointestinal Tract Involvement in Inflammatory Bowel Diseases: Histologic Clues and Pitfalls.

Authors:  Bence Kővári; Rish K Pai
Journal:  Adv Anat Pathol       Date:  2022-01-01       Impact factor: 3.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.